Evidence map›Paper›PMID 34569154›Full record

ArticleMolecular systems biology2021

A highly multiplexed quantitative phosphosite assay for biology and preclinical studies.

Hasmik Keshishian, E Robert McDonald, Filip Mundt, Randy Melanson, Karsten Krug, Dale A Porter, Luke Wallace, Dominique Forestier, Bokang Rabasha, Sara E Marlow and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular systems biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. An Introduction to Advanced Targeted Acquisition Methods.Molecular & cellular proteomics : MCP · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 3 institutions in 1 country.

Hasmik KeshishianBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0062-9867
E Robert McDonaldNovartis Institute of Biomedical Research, Cambridge, MA, USA.
Filip MundtBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Randy MelansonBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Karsten KrugBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Dale A PorterNovartis Institute of Biomedical Research, Cambridge, MA, USA.
Luke WallaceBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Dominique ForestierBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Bokang RabashaBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Sara E MarlowBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Judit Jane-ValbuenaBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Ellen TodresBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Harrison SpechtBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0003-3151-6803
Margaret Lea RobinsonBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0002-4019-3770
Pierre M Jean BeltranBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Ozgun BaburComputer Science Department, University of Massachusetts Boston, Boston, MA, USA.ORCID 0000-0002-0239-5259
Meagan E OliveBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8287-9474
Javad GoljiNovartis Institute of Biomedical Research, Cambridge, MA, USA.
Eric KuhnBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Michael BurgessBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Melanie A MacMullanBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0001-5296-5902
Tomas RejtarNovartis Institute of Biomedical Research, Cambridge, MA, USA.
Karen WangNovartis Institute of Biomedical Research, Cambridge, MA, USA.ORCID 0000-0002-0839-5284
D R ManiBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Shankha SatpathyBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0002-6040-4854
Michael A GilletteBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9300-1448
William R SellersBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Steven A CarrBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7203-4299
Broad Institute · USNovartis (United States) · USUniversity of Massachusetts Boston · US

Funding

MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALSU01CA214125 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ANURAG, MEENAKSHI, CARR, STEVEN A · 2017 to 2021
$7.0M
Center of Excellence for High Throughput Proteogenomic CharacterizationU24CA210986 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, GILLETTE, MICHAEL A · 2016 to 2020
$6.4M
Integrated high throughput proteogenomic data analysis center for CPTACU24CA210979 · NCI · BROAD INSTITUTE, INC. · PI BIRGER, CHET, GETZ, GAD A · 2016 to 2020
$4.4M
NCI NIH HHS U01 CA214125NCI NIH HHS U24 CA210979NCI NIH HHS U24 CA210986
6 · The paper itself

Abstract

Reliable methods to quantify dynamic signaling changes across diverse pathways are needed to better understand the effects of disease and drug treatment in cells and tissues but are presently lacking. Here, we present SigPath, a targeted mass spectrometry (MS) assay that measures 284 phosphosites in 200 phosphoproteins of biological interest. SigPath probes a broad swath of signaling biology with high throughput and quantitative precision. We applied the assay to investigate changes in phospho-signaling in drug-treated cancer cell lines, breast cancer preclinical models, and human medulloblastoma tumors. In addition to validating previous findings, SigPath detected and quantified a large number of differentially regulated phosphosites newly associated with disease models and human tumors at baseline or with drug perturbation. Our results highlight the potential of SigPath to monitor phosphoproteomic signaling events and to nominate mechanistic hypotheses regarding oncogenesis, response, and resistance to therapy.

Indexed as

PhosphoproteinsProteomicsHumansMass SpectrometryPhosphorylationSignal TransductionPhosphoproteinsbreast cancerCPTACmedulloblastomapost-translational modificationstargeted mass spectrometry

Identifiers

PMID34569154
PMCPMC8474009
OpenAlexW3202975194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.